Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Regulation01:25

Drug Regulation

1.9K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.9K
Drug Control Governance: Regulatory Bodies and Their Impact01:03

Drug Control Governance: Regulatory Bodies and Their Impact

258
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
258
Pharmacovigilance01:19

Pharmacovigilance

1.0K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.0K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

184
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
184
Global Regulatory Systems01:28

Global Regulatory Systems

83
Global regulatory systems in bacteria enable rapid and coordinated responses to environmental changes by integrating sensory inputs with gene expression, ensuring efficient adaptation to fluctuating conditions. Key global regulatory mechanisms include regulons, two-component systems, sigma factors, and secondary messengers.Regulons and Global RegulatorsA regulon is a collection of genes and operons controlled by a common global regulator. These regulators enable bacteria to prioritize resource...
83
Clinical Trials: Overview01:11

Clinical Trials: Overview

3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of mode of birth and perinatal antibiotics on infant gut microbiota and health: a systematic review and meta-analysis.

BMJ paediatrics open·2026
Same author

The association between diverse dietary quality measures and the presence of acute or chronic pain in the UK Biobank.

The journal of pain·2026
Same author

Point-Of-Care Testing of Fibrinogen by the qLab FIB System in Patients Taking Direct Oral Anticoagulants (DOACs).

International journal of laboratory hematology·2026
Same author

Evaluating the peripheral nervous system pathology of Alzheimer's disease utilizing a functional human NMJ microphysiological system.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Dermisichthinium pseudosporum gen. et sp. nov. (Dinophyceae, Suessiaceae): a dinoflagellate parasite in freshwater fish in Wisconsin, USA.

Diseases of aquatic organisms·2025
Same author

Developing a functional non-animal CNS stress model utilizing long-term potentiation with human iPSC-cortical neurons to evaluate therapeutics.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2025

Related Experiment Video

Updated: Sep 18, 2025

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
09:30

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

3.7K

Tracking a Medicine's Regulatory Risk Management Commitments Provides Better Transparency and Oversight.

Simon Ingate1, Kate Bendall2, Christopher Long3

  • 1Axian Consulting Limited, The Bradfield Centre, 184 Cambridge Science Park, Cambridge, CB2 0GA, UK. singate@axian.consulting.

Therapeutic Innovation & Regulatory Science
|June 20, 2025
PubMed
Summary

Pharmaceutical companies must manage complex Risk Management Plans (RMPs) and additional risk minimization materials (aRMMs). A new database system streamlines tracking and deployment of these crucial drug safety documents.

Keywords:
Additional risk minimisation measuresRisk management commitmentsRisk minimisationTracking

More Related Videos

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
06:37

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Published on: September 15, 2023

740
High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
10:17

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

Published on: April 23, 2019

9.8K

Related Experiment Videos

Last Updated: Sep 18, 2025

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
09:30

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

3.7K
Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
06:37

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Published on: September 15, 2023

740
High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
10:17

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

Published on: April 23, 2019

9.8K

Area of Science:

  • Pharmacovigilance and Drug Safety
  • Regulatory Affairs
  • Health Informatics

Background:

  • Pharmaceutical companies require Risk Management Plans (RMPs) for marketing authorisation, detailing efficacy, safety, and post-authorisation pharmacovigilance (PV) commitments.
  • RMPs evolve with new data and indications, leading to multiple versions, and may require additional risk minimization materials (aRMMs) for healthcare professionals and patients.
  • Implementing RMPs and aRMMs globally involves complex localisation, regulatory approval, dissemination, and effectiveness tracking, posing significant data management challenges.

Purpose of the Study:

  • To explore the development and deployment of a database-driven system for tracking Risk Management Plans (RMPs) and additional risk minimization materials (aRMMs).
  • To address the critical data management issues arising from managing multiple versions of RMPs and aRMMs and associated global activities.
  • To assess the impact of implementing such a system on pharmaceutical organizations.

Main Methods:

  • Systematic determination of requirements for a database-driven RMP and aRMM tracking system.
  • Development and deployment of the proposed tracking system.
  • Assessment of the system's impact on organizational processes and data management.

Main Results:

  • The development and implementation of a database-driven system effectively manage multiple RMP and aRMM versions.
  • Improved tracking of document status and locally agreed activities across different markets.
  • Demonstrated positive impact on organizational efficiency in managing global risk management commitments.

Conclusions:

  • A database-driven tracking system is vital for efficiently managing complex RMPs and aRMMs in the pharmaceutical industry.
  • The system enhances understanding and control over drug benefit-risk profiles through streamlined pharmacovigilance activities.
  • Successful implementation leads to improved regulatory compliance and operational efficiency in global drug safety management.